GT Biopharma, Inc. (GTBP) stock
GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.18−0.35 (-10.04%)
Close on Nov 17, 2026Market cap $143.45MP/E –Yield –
GT Biopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
GT Biopharma's enterprise value was $94.05M on Nov 11, 2026, against $117.01M a year earlier. Over the last 5 years it ranged from $42.67M to $2.52B, with a median of $192.18M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $94.05M | -19.1% |
| 2025 | Dec 31, 2025 | $116.27M | -29.0% |
| 2024 | Dec 31, 2024 | $163.86M | -33.9% |
| 2023 | Dec 29, 2023 | $248.07M | -65.6% |
| 2022 | Dec 30, 2022 | $720.79M | +83.7% |
| 2021 | Dec 31, 2021 | $392.45M | -97.2% |
| 2020 | Dec 31, 2020 | $13.97B | +506.7% |
| 2019 | Dec 31, 2019 | $2.30B | -83.4% |
| 2018 | Dec 31, 2018 | $13.88B | -85.3% |
| 2017 | Dec 29, 2017 | $94.14B | – |
See a number that looks wrong?